News

The MOMS Spina Bifida Trial Seeks Pregnant Enrollees


 

The Management of Myelomeningocele Study (MOMS) is a randomized, controlled clinical trial that continues to enroll pregnant women between 19 and 25 weeks' gestation. Funded by the National Institute of Child Health and Human Development, the trial will compare the safety and efficacy of prenatal versus postnatal closure of myelomeningocele. Participating MOMS centers are the Children's Hospital of Philadelphia; Vanderbilt University Medical Center in Nashville, Tenn.; and the University of California at San Francisco.

To refer a patient or for more information, contact study coordinator Jessica Ratay at 866-275-6667 or MOMS@bsc.gwu.eduwww.spinabifidamoms.com

Recommended Reading

Risks, Benefits of BRCA Genetic Testing Weighed
MDedge ObGyn
PPI Use, Fracture Risk Tied to Other Risk Factors
MDedge ObGyn
PPI-Associated Adverse Effects Are Overstated, Expert Says
MDedge ObGyn
Ovarian Ca Screen Could Detect Early Disease
MDedge ObGyn
FDA Warns on Fracture Risks With PPIs
MDedge ObGyn
Improving Survival in Cervical Cancer Patients
MDedge ObGyn
DXA More Accurate Than BMI to Measure Obesity
MDedge ObGyn
Small Study: Antiepileptics Interfere With OCs
MDedge ObGyn
Bevacizumab Plus Chemo Ups Ovarian Cancer Survival
MDedge ObGyn
Is the HPV test effective as the primary screen for cervical cancer?
MDedge ObGyn